ClinicalTrials.gg
RecruitingNCT07575503Updated May 8, 2026

Diagnostic Value of Photon-Counting CT in Subsegmental Pulmonary Embolism

An observational study in Subsegmental Pulmonary Embolism and Photon-Counting Computed Tomography, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University · Observational

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
696
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 72 studies in Pulmonary Embolism with a site in China — 26 open to participants now, 31 under way, 1 of them phase 3. Pulmonary Embolism · China.

Planned enrollment
23rd of 39
696 · median 1,000
Started
2026
with 6 others
Observational
39 of 72
20 open now
Primary completion
2026-09
later than 11 of 30 live
Registered
67th of 72
by date

Among the 72 studies in Pulmonary Embolism with a site in China, this one is the 23rd largest by planned enrollment of the 39 observational ones that give a count, is one of 7 that started in 2026, is one of 39 observational ones, reaches primary completion later than 11 of the 30 other live ones, and was the 67th registered.

Pulmonary Embolism

833 studies on the registry are indexed under Pulmonary Embolism; 172 are open to participants now.

Browse Pulmonary Embolism studies →

Open to participants now

26 of the 72 studies in Pulmonary Embolism with a site in China are open now. Recruiting first, the newest first:

20 more — sign in →

All 26 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 130 Pulmonary Embolism studies recruiting now, 110 (85%) set no upper age limit and 5 (4%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Pulmonary Embolism with a site in China, or all of them as a file.
02

Study summary

Pulmonary embolism (PE) is a serious and potentially life-threatening condition caused by blood clots in the lungs. A particular type, subsegmental pulmonary embolism (SSPE), involves very small branches of the pulmonary arteries. Although these clots occur in smaller vessels, their risk of recurrence and complications may be similar to larger clots.

Conventional CT pulmonary angiography (CTPA) is the standard imaging test for suspected PE, but image quality can sometimes be limited by motion artifacts, poor contrast filling, or body habitus, making the detection of SSPE challenging.

Photon-counting computed tomography (PCCT) is a new CT technology that provides higher image resolution, lower radiation dose, and improved visualization of small blood vessels. Early studies suggest PCCT may reduce motion artifacts and increase the accuracy of detecting SSPE compared with conventional CT.

This prospective cohort study will compare PCCT with dual-source CT in patients with suspected acute PE. The study aims to determine whether PCCT improves the detection rate and image quality for SSPE, and whether it can provide more reliable diagnostic information to guide clinical care.

Read the detailed description

Pulmonary embolism (PE) is a leading cause of morbidity and mortality worldwide. Subsegmental pulmonary embolism (SSPE), defined as thrombi confined to subsegmental pulmonary arteries, may account for up to 20% of acute PE cases detected by multidetector CT. While distal in location, SSPE carries a risk of recurrent venous thromboembolism and mortality that is comparable to more proximal PE, suggesting that SSPE is not a benign entity. Accurate diagnosis is therefore clinically important, but remains challenging due to motion artifacts, poor contrast opacification, and the large number of small subsegmental vessels that must be evaluated.

Photon-counting computed tomography (PCCT) is a recently developed imaging technology that offers significant improvements over conventional energy-integrating detector CT (EID-CT). PCCT provides higher spatial resolution, direct spectral information, and the ability to generate virtual monoenergetic images and iodine maps in a single acquisition, while reducing radiation dose. Preliminary studies indicate that PCCT can minimize motion artifacts, improve image quality, and enhance visualization of small pulmonary arteries, potentially increasing the detection of SSPE.

This prospective observational cohort study will compare the diagnostic performance of PCCT with dual-source CT in patients with suspected acute PE. The primary outcome is the detection rate of SSPE. Secondary outcomes include image quality scores, radiation dose, and the added diagnostic value of PCCT in patients with negative findings on dual-source CT. By systematically evaluating image quality, detection yield, and radiation exposure, this study seeks to establish the potential role of PCCT as a superior diagnostic tool for SSPE in real-world clinical practice.

03

Conditions studied

  • Subsegmental Pulmonary Embolism
  • Photon-Counting Computed Tomography

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults (≥18 years) presenting with clinical symptoms and signs suggestive of acute pulmonary embolism will be enrolled. Eligible patients are those with a simplified revised Geneva score ≥3 and abnormal findings on electrocardiogram, echocardiography, or pulse oximetry, which support the suspicion of pulmonary embolism. Patients will be prospectively recruited from the emergency department and inpatient wards of the Second Affiliated Hospital, Zhejiang University School of Medicine. The study population is representative of patients with suspected acute pulmonary embolism who require CT pulmonary angiography for diagnostic confirmation.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years
  2. Clinical manifestations supporting the diagnosis of acute pulmonary embolism, including:

    Acute onset or progressive dyspnea Unexplained hypoxemia Chest pain Hemoptysis Syncope or presyncope Combined with abnormal findings on , echocardiography, or pulse oximetry

  3. Revised simplified Geneva score ≥ 3
  4. Written obtained from the patient or the patient's legally authorized representative

Exclusion criteria

Exclusion Criteria:

  1. Patients requiring prophylactic or therapeutic doses of anticoagulant medication for reasons other than venous thromboembolism (VTE).
  2. less than three months.
  3. Patients unable to undergo CT scanning due to severe condition or hemodynamic instability.
  4. History of allergy to contrast media, renal insufficiency ( \< 30 mL/min), or ongoing long-term dialysis.
  5. Pregnancy.
  6. Refusal to provide or inability to complete follow-up for any reason.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
696 participants (estimated)
Patient registry
No

Groups and cohorts

  • Group 1Title: Conventional CT group

    Description: Patients with suspected pulmonary embolism who undergo dual-source or energy-integrating detector CT pulmonary angiography (EID-CTPA).

  • Group 2 Title: Photon-counting CT group

    Description: Patients with suspected pulmonary embolism who undergo photon-counting computed tomography (PCCT) for diagnosis.

06

What researchers measure

Primary outcomes

  1. Detection rate of subsegmental pulmonary embolism (SSPE) using photon-counting CT versus dual-energy CT

    The proportion of patients with suspected acute pulmonary embolism in whom SSPE is detected on photon-counting CT compared with dual-energy CT. All scans will be independently assessed by two blinded radiologists to determine diagnostic yield.

    Time frame: perioperative period

Secondary outcomes

  1. Objective image quality scores for SSPE diagnosis

    ignal-to-Noise Ratio (SNR) and Contrast-to-Noise Ratio (CNR) will be calculated based on CT attenuation and image noise measured in standardized Regions of Interest (ROIs) within pulmonary vessels, the aorta, and paraspinal muscles. Higher SNR and CNR values indicate better objective image quality.

    Time frame: perioperative period

  2. Subjective image quality scores for SSPE diagnosis

    Radiologists will qualitatively assess image noise and motion artifacts using a 5-point Likert scale (1 = Unacceptable, 5 = Excellent). The average score of the readers will be used, with higher scores indicating better subjective image quality

    Time frame: perioperative period

  3. Incidence of Venous Thromboembolism (VTE)

    Occurrence of symptomatic VTE, defined as Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE), confirmed by objective imaging upon clinical suspicion

    Time frame: 3 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Sep 2026, 8 months after the start.

Of 135 non-industry observational studies under Pulmonary Embolism, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 119. This study's planned 8 months is below that.

Counting every sponsor, half of 160 studies reached it within 47 months; a quarter within 21 and three quarters within 105.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
May 8, 2026
StartActual
Jan 1, 2026
Primary completionEst.
Sep 2026
CompletionEst.
Jan 2027
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07575503
Responsible party
Sponsor
First posted
May 8, 2026
Start date
Jan 1, 2026
Primary completion
Sep 2026 (estimated)
Completion
Jan 2027 (estimated)
Last update
May 8, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion